Bifogade filer
Elekta Q2 Report 23 24
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Large Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Continued profitable growth
We continued to deliver on our strategy, ACCESS 2025, and drive significant improvements in the second quarter, the fourth consecutive quarter with revenue growth and expanded EBIT margin. Order growth came back, supported by large deals in both India and Ukraine, and cash flow improved.
Gustaf Salford
President and CEO
Second quarter
- Gross order intake increased by 9 percent to SEK 4,989 M (4,598), corresponding to a 4 percent increase in constant exchange rates
- Net sales increased by 16 percent to SEK 4,732 M (4,081), corresponding to a 10 percent increase in constant exchange rates
- Adjusted gross margin amounted to 36.0 percent (37.3)
- Adjusted operating income (Adjusted EBIT) amounted to SEK 542 M (316), corresponding to an adjusted EBIT margin of 11.5 percent (7.7)
- Earnings per share was SEK 0.90 (0.32) before/after dilution
- Adjusted earnings per share was SEK 0.94 (0.55) before/after dilution
- Cash flow after continuous investments amounted to SEK 211 M (-417)
First six months
- Gross order intake increased by 4 percent to SEK 8,828 M (8,468), corresponding to a 1 percent decrease in constant exchange rates
- Net sales increased by 16 percent to SEK 8,560 M (7,408), corresponding to a 9 percent increase in constant exchange rates
- Adjusted gross margin amounted to 38.5 percent (38.1)
- Adjusted operating income (Adjusted EBIT) amounted to SEK 969 M (447), corresponding to an adjusted EBIT margin of 11.3 percent (6.0)
- Earnings per share was SEK 1.52 (0.47) before/after dilution
- Adjusted earnings per share was SEK 1.59 (0.74) before/after dilution
- Cash flow after continuous investments amounted to SEK -688 M (-1,010)
| Group summary | Q2 | 6 months | ||||||
| SEK M | 2023/24 | 2022/23 | Δ | 2023/24 | 2022/23 | Δ | ||
| Gross order intake | 4,989 | 4,598 | 4% | 1 | 8,828 | 8,468 | -1% | 1 |
| Net sales | 4,732 | 4,081 | 10% | 1 | 8,560 | 7,408 | 9% | 1 |
| Adjusted gross margin 2 | 36.0% | 37.3% | -1,4 ppts | 38.5% | 38.1% | 0,4 ppts | ||
| Adjusted EBITDA 3 | 817 | 582 | 40% | 1,524 | 975 | 56% | ||
| Adjusted EBITDA-margin 3 | 17,3% | 14,3% | 3 ppts | 17,8% | 13,2% | 4,6 p.e. | ||
| Adjusted EBIT 4 | 542 | 316 | 72% | 969 | 447 | 117% | ||
| Adjusted EBIT margin 4 | 11,5% | 7,7% | 3,7 ppts | 11,3% | 6,0% | 5,3 ppts | ||
| Gross margin | 35.8% | 36.2% | -0,4 ppts | 38.4% | 37.4% | 1 ppts | ||
| EBITDA | 800 | 465 | 72% | 1,493 | 844 | 77% | ||
| EBITDA-margin | 16,9% | 11,4% | 5,5 ppts | 17,4% | 11,4% | 6 p.e. | ||
| EBIT | 525 | 199 | 163% | 937 | 316 | 196% | ||
| EBIT margin | 11,1% | 4,9% | 6,2 ppts | 10,9% | 4,3% | 6,7 ppts | ||
| Cash flow after continuous investments | 211 | -417 | 628 | -688 | -1,010 | 322 | ||
| Adjusted earnings per share before/after dilution, SEK 5 | 0.94 / 0.94 | 0.55 / 0.55 | 68% | 1.59 / 1.59 | 0.74 / 0.74 | 114% | ||
| Earnings per share before/after dilution, SEK | 0.90 / 0.90 | 0.32 / 0.32 | 183% | 1.52 / 1.52 | 0.47 / 0.47 | 221% | ||
1 Compared to last fiscal year based on constant exchange rates.
2 Adjusted gross margin = Gross margin excluding items affecting comparability attributable to the Cost-reduction Initiative within the Resilience and Excellence Program, see page 29.
3 Adjusted EBITDA = EBITDA excluding items affecting comparability attributable to the Cost-reduction Initiative within the Resilience and Excellence Program, see page 30.
4 Adjusted EBIT = Operating income (EBIT) excluding items affecting comparability, see page 30.
5 Adjusted earnings per share = Net income attributable to Parent Company shareholders, excluding items affecting comparability, in relation to the weighted average number of shares (excluding treasury shares), see page 31.
# # #
For further information, please contact:
Tobias Hägglöv, CFO
Tel: +46 76 107 4799, e-mail: tobias.hagglov@elekta.com
Time zone: CET: Central European Time
Cecilia Ketels, Head of Investor Relations
Tel: +46 76 611 76 25, e-mail: cecilia.ketels@elekta.com
Time zone: CET: Central European Time
About Elekta
As a leader in precision radiation therapy, Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable, outcome-driven and cost-efficient solutions to meet evolving patient needs, improve lives and bring hope to everyone dealing with cancer. To us, it's personal, and our global team of 4,500 employees combine passion, science, and imagination to profoundly change cancer care. We don’t just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in more than 40 countries and listed on Nasdaq Stockholm. For more information, visit elekta.com or follow @Elekta on “X”, formerly known as Twitter.